PC
TEVA icon

PointState Capital’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

PointState Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,672,100
Closed -$115M – 66
2025
Q4 		$115M Hold
3,672,100
– – 1.69% 28
2025
Q3 		$74.2M Hold
3,672,100
– – 1.11% 32
2025
Q2 		$61.5M Hold
3,672,100
– – 0.94% 31
2025
Q1 		$56.4M Buy
3,672,100
+1,172,100
+47% +$20.9M 0.82% 35
2024
Q4 		$55.1M Hold
2,500,000
– – 1% 30
2024
Q3 		$45M Hold
2,500,000
– – 0.82% 28
2024
Q2 		$40.6M Buy
+2,500,000
New +$38.5M 0.88% 36
2016
Q4 		– Sell
-36,500
Closed -$1.68M – 161
2016
Q3 		$1.68M Buy
+36,500
New +$1.9M 0.02% 136

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

PointState Capital's TEVA Position: Q2 2026 in Review

PointState Capital sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2026, closing a stake of 1,973,782 shares — an estimated $59.5M sold.

PointState Capital first reported a position in TEVA in Q4 2013 and held it in 22 quarters. The position peaked at $751M in Q2 2016. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • PointState Capital reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2026 after selling out during the quarter.
  • PointState Capital sold 1,973,782 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $59.5M.
  • PointState Capital first reported a position in Teva Pharmaceutical Industries Limited in Q4 2013 and held it in 22 quarters.
  • PointState Capital's Teva Pharmaceutical Industries Limited position peaked at $751M in Q2 2016.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on PointState Capital's 13F filing for Q2 2026, filed 14 Aug 2026.